Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Target Lesion Clear all
Withdrawn Phase 1Phase 2 Interventional

Comparing Two Treatments That Both Target Smoking Cessation and Weight Loss at the Same Time.

NCT04130698
View directory record Official record
Conditions
Smoking Cessation, Weight Loss
Interventions
Distress Tolerance, transdermal nicotine patch, Active Health Control
Behavioral · Drug
Lead sponsor
Rhode Island College
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01076647
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
66
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 22, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

OCD LIFU Target Engagement

NCT07558148
View directory record Official record
Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
Low Intensity Focused Ultrasound
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

NCT01028885
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
radiation therapy treatment planning/simulation, intensity-modulated radiation therapy, image-guided radiation therapy, magnetic resonance imaging, computed tomography
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 22, 2026, 11:12 PM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 22, 2026, 11:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

NCT06238921
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Amplification of Positivity to Enhance Social Connections in Anxiety and Depression

NCT04945239
View directory record Official record
Conditions
Depression, Anxiety Disorders and Symptoms
Interventions
Amplification of Positivity Training (6 Sessions), Stress Management Training (6 Sessions)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

NCT00396097
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Genotropin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 10 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
43
States / cities
Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 22, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

Pain and Major Depressive Disorder

NCT04556890
View directory record Official record
Conditions
Major Depressive Disorder, Chronic Pain
Interventions
Active rTMS/Active iTBS DFPLC/Sham Pain M1, Active rTMS/Active iTBS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 22, 2026, 11:12 PM EDT
Enrolling by invitation Not applicable Interventional

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder

NCT06572683
View directory record Official record
Conditions
MDD, Depression
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 11:12 PM EDT
Active, not recruiting Not applicable Interventional

Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

NCT04562532
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Microport Firehawk stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Device
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

NCT03635866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluciclovine PET/MRI
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 22, 2026, 11:12 PM EDT
Terminated Not applicable Interventional Results available

Utilization of Target Ranges to Treat Parkinson's Disease With the PKG

NCT03984305
View directory record Official record
Conditions
Parkinson Disease
Interventions
Personal KinetiGraph® (PKG®) Watch, Personal KinetiGraph® (PKG®) Report
Device
Lead sponsor
Global Kinetics Corporation
Industry
Eligibility
46 Years to 83 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Menlo Park, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691
View directory record Official record
Conditions
Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
181
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2007 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

NCT01836523
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery

NCT01097525
View directory record Official record
Conditions
Myopia, Myopic Astigmatism
Interventions
WFG PRK, WFG LASIK, WFO PRK, WFO LASIK
Procedure
Lead sponsor
Fort Belvoir Community Hospital
Federal
Eligibility
21 Years to 55 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Web-based Interpretation Training For Anxiety

NCT02382003
View directory record Official record
Conditions
Anxiety
Interventions
Positive Cognitive Bias Modification - Interpretation, 50/50 Cognitive Bias Modification - Interpretation, Anxious Imagery Prime, Neutral Imagery Prime
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feelings About Exercise

NCT03598647
View directory record Official record
Conditions
Physical Activity, Obesity
Interventions
Affect and physical activity, Physical activity information
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 22, 2026, 11:12 PM EDT
Recruiting Phase 3 Interventional

Vitamin D and Type 2 Diabetes - Treat-To-Target

NCT07448974
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes (T2DM)
Interventions
Vitamin D (Cholecalciferol ), Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years to 74 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 11:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

NCT01354613
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions
Dobutamine, Amlodipine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 22, 2026, 11:12 PM EDT
Suspended Phase 2 Interventional

Terazosin And Metabolic Energetics in Parkinson's Disease

NCT07464028
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Terazosin 5 MG, Placebo
Drug
Lead sponsor
Ergun Y. Uc
Other
Eligibility
50 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 11:12 PM EDT